Neurocrine Biosciences reported a strong fiscal year 2025, with total product sales exceeding $2.8 billion, representing 22% year-over-year growth. This performance was driven by INGREZZA, which generated $2.5 billion in revenue (up 9%), and the exceptional launch of CRENESSITY, which achieved over $300 million in sales in its first full year. The company maintained robust profitability with a non-GAAP operating margin of approximately 30% ($850 million in income) and ended the year with $2.5 billion in cash. For 2026, management guides for INGREZZA sales of $2.7 billion to $2.8 billion (approx. 10% growth) but withheld specific guidance for CRENESSITY, citing the 'learning launch' nature of the rare disease market. Strategic priorities include expanding the sales force, advancing Phase III programs for osavampator and direclidine with data expected in 2027, and developing next-generation VMAT2 inhibitors.
| Metric | Value | Change |
|---|---|---|
| Total Product Sales (2025) | $2.8 Billion | +22% YoY |
| INGREZZA Sales (2025) | $2.5 Billion | +9% YoY |
| CRENESSITY Sales (2025) | $300 Million | First Full Year |
| Non-GAAP Operating Margin | 30% | ~$850M Income |
| Cash Position | $2.5 Billion | +$700M YoY |
| INGREZZA 2026 Guidance | $2.7 - $2.8 Billion | ~10% Growth |
Neurocrine is executing a successful diversification strategy, transitioning from a reliance on INGREZZA to a multi-product platform. The launch of CRENESSITY is a critical strategic pillar, having generated over $300 million in its first year and capturing approximately 10% of the addressable classic CAH population. Management emphasized that CRENESSITY's profile—first-in-disease in 70 years, strong safety, and no titration—mirrors the successful launch trajectory of INGREZZA, positioning it to become the company's second blockbuster.
The company is aggressively defending and expanding its VMAT2 franchise. Despite being 9 years post-launch, INGREZZA achieved record new prescriptions and is expected to grow 10% in 2026. Management highlighted head-to-head PET imaging data showing INGREZZA has nearly double the target occupancy of AUSTEDO XR, reinforcing a clinical differentiation strategy to combat competitive pressures, particularly as AUSTEDO enters Medicare negotiated pricing in 2027.
Significant investments are being made in the commercial infrastructure to sustain growth. The company is completing a sales force expansion by the end of Q1 2026 to support both INGREZZA and CRENESSITY. For CRENESSITY, this includes leveraging AI to identify patients managed by primary care or OB-GYNs, acknowledging that while endocrinologists are central, a portion of the patient base lies outside specialty care.
The pipeline is maturing into a late-stage catalyst engine. Management designated 2027 as a 'data-rich year,' with top-line results expected for osavampator (Major Depressive Disorder) and direclidine (Schizophrenia). The company is also advancing next-generation VMAT2 inhibitors (NBI-890, NBI-675) into Phase II, aiming for long-acting injectable formulations to address compliance issues and expand the market.
Management declined to provide specific sales guidance for CRENESSITY in 2026, despite the drug exceeding expectations in its first year. While they cited the 'learning launch' nature of a first-in-disease therapy and lack of seasonality data, this lack of visibility introduces uncertainty for investors modeling the growth trajectory of the company's key growth driver. Analysts pressed for details on early 2026 trends and potential seasonality, but management remained opaque on specific metrics.
INGREZZA faces persistent pricing headwinds that will dampen revenue growth despite volume increases. Management guided for a negative 4% price impact in 2026 due to formulary access concessions made in 2025. Furthermore, the impending inclusion of competitor AUSTEDO in the Medicare negotiated price list for 2027 poses a risk to formulary positioning and market share, requiring Neurocrine to rely heavily on clinical differentiation (receptor occupancy data) to maintain access.
While CRENESSITY has reached 1,000 prescribers, adoption depth is a current challenge. Management noted that two-thirds of these prescribers have treated only one patient. This suggests that community endocrinologists, who often have few CAH patients, may be hesitant to broaden usage or lack sufficient patient identification capabilities. This 'inch deep and a mile wide' prescriber base requires heavy investment in education and field force expansion to convert single-prescribers into high-volume prescribers.
R&D expenses are set to rise significantly in 2026 to support Phase III programs for osavampator and direclidine. While these are necessary for long-term growth, the increased spend, combined with SG&A investments for sales force expansion, will pressure operating margins which have been exceptionally high (~30%). The success of these increased expenditures hinges entirely on data readouts in 2027, creating a near-term risk of rising costs without immediate revenue offset.
Overall: Management exhibited a highly confident and enthusiastic demeanor throughout the call, frequently describing the company's position as the 'strongest foundation in Neurocrine's history.' The tone shifted from celebratory during prepared remarks—highlighting record prescriptions and successful launches—to a more cautious but optimistic stance during the Q&A regarding CRENESSITY's trajectory and INGREZZA's pricing environment.
Confidence: HIGH - Executives used definitive language regarding the durability of INGREZZA and the potential of CRENESSITY to become a blockbuster. They provided specific financial guidance and clear timelines for pipeline data, indicating strong internal visibility and control over execution.
$2.7 billion to $2.8 billion (approx. 10% growth)
Not provided (Learning launch)
Low 40% of sales
Mid-30% of sales (excl. milestones)
Relatively consistent with exit 2025 levels; approx. -4% YoY impact
Hedging & Uncertainty: Management employed hedging primarily regarding the forward-looking trajectory of CRENESSITY, using qualifiers like 'learning launch,' 'ebbs and flows,' and 'too early to call' when discussing seasonality and guidance. However, they used very definitive language when discussing INGREZZA's resilience ('record year,' 'strong foundation') and the pipeline's potential ('shaping up to be the most data-rich year'). A notable example of defensive hedging occurred when the CFO stated, 'Let's not confuse not providing guidance with not expecting significant growth this year,' attempting to manage investor expectations without committing to a specific number.
A hallmark of a healthy company is the strength of the foundation beneath it. - Kyle Gano, Chief Executive Officer
We anticipate meaningful steady new patient additions every single quarter that's going to lead to a very nice growth year. - Matthew Abernethy, Chief Financial Officer
So what's next? - Eric Benevich, Chief Commercial Officer
We're watching the progress of Cobenfy in AD psychosis quite carefully. - Sanjay Keswani, Chief Medical Officer
I'm really hard-pressed to see any medicine that delivers on the profile of CRENESSITY and is displaced at all by any future medicine. - Kyle Gano, Chief Executive Officer
Analyst Sentiment: Analysts were largely congratulatory regarding the strong INGREZZA performance and the surprise upside of CRENESSITY's launch. However, there was persistent skepticism and probing regarding the lack of CRENESSITY guidance, with multiple analysts attempting to pin down management on seasonality, early Q1 trends, and the 'early bolus' theory.
Management Responses: Management remained disciplined in deflecting specific CRENESSITY numbers, repeatedly referring to the 'learning launch' narrative and the precedent set by INGREZZA. They were more transparent regarding INGREZZA pricing mechanics and the competitive landscape against AUSTEDO. Responses were generally detailed and confident, though they carefully avoided quantifying the uncertain elements of the new CAH market.
Analysts pressed heavily on the decision not to guide CRENESSITY, asking for specific data on the first 6 weeks of 2026 and whether an 'early launch bolus' had occurred. Management deflected, stating they need more quarters to understand seasonality and that they anticipate 'meaningful steady new patient additions' without giving a number.
There was significant focus on the competitive dynamics between INGREZZA and AUSTEDO, specifically regarding the recent head-to-head PET imaging data showing superior receptor occupancy for INGREZZA. Management used this to argue for clinical superiority as a buffer against future pricing pressure in 2027.
Questions regarding the depth of CRENESSITY adoption were prominent, specifically why 2/3 of prescribers had only written one script. Management explained this as a function of low patient volume in community endo practices and the need for education and AI-driven patient finding.
Neurocrine Biosciences has successfully evolved into a diversified biopharma powerhouse with a durable commercial foundation. The core thesis rests on the continued resilience of INGREZZA, which is defying maturity expectations with 9% growth and a clear path to 10% growth in 2026 despite pricing headwinds. The CRENESSITY launch is a transformative success, validating the company's commercial capabilities in rare diseases; while the lack of 2026 guidance creates near-term uncertainty, the rapid uptake (10% market share in year one) and strong persistence signal a high probability of blockbuster status. The pipeline offers a second wave of growth with 2027 catalysts in depression and schizophrenia. The company's strong balance sheet ($2.5B cash) and high profitability provide a safety cushion to fund these investments. Risks include competitive pressure from AUSTEDO in 2027 and the execution risk associated with ramping a rare disease franchise, but the risk/reward remains attractive.
Management acknowledged the impact of Medicare negotiated pricing on the competitive landscape, specifically noting that AUSTEDO will become a negotiated product in 2027. This creates a potential deflationary pricing environment for the VMAT2 class, forcing Neurocrine to rely on formulary access and clinical differentiation (receptor occupancy data) to maintain share.
Neurocrine is successfully navigating the complex rare disease market for CAH by leveraging AI and technology to identify patients outside of specialized endocrinology centers (e.g., PCPs, OB-GYNs). This reflects a broader industry trend of using advanced data analytics to unlock 'hidden' patient populations in fragmented care settings.